vs
MATTHEWS INTERNATIONAL CORP（MATW）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
MATTHEWS INTERNATIONAL CORP的季度营收约是Pacira BioSciences, Inc.的1.6倍（$284.8M vs $177.4M），MATTHEWS INTERNATIONAL CORP净利率更高（15.3% vs 1.6%，领先13.7%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -29.1%）
马修斯国际旗下的马修斯奥罗拉殡葬解决方案公司是美国规模最大的棺材与骨灰瓮生产商之一，2005年的数据显示其棺材产品占据美国市场超38%的份额，总部位于印第安纳州奥罗拉。该公司同时生产木质、金属棺材与骨灰瓮产品，也为殡葬机构提供殡葬用品供应与咨询服务。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
MATW vs PCRX — 直观对比
营收规模更大
MATW
是对方的1.6倍
$177.4M
营收增速更快
PCRX
高出34.1%
-29.1%
净利率更高
MATW
高出13.7%
1.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $284.8M | $177.4M |
| 净利润 | $43.6M | $2.9M |
| 毛利率 | 35.0% | — |
| 营业利润率 | 34.2% | 3.9% |
| 净利率 | 15.3% | 1.6% |
| 营收同比 | -29.1% | 5.0% |
| 净利润同比 | 1356.6% | — |
| 每股收益（稀释后） | $1.39 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATWPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $284.8M | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | — | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | — | $168.6M | ||
| Q2 24 | — | $178.0M |
净利润MATWPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $43.6M | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | — | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-143.5M | ||
| Q2 24 | — | $18.9M |
毛利率MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | 35.0% | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
营业利润率MATWPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 34.2% | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | -82.8% | ||
| Q2 24 | — | 15.9% |
净利率MATWPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -85.1% | ||
| Q2 24 | — | 10.6% |
每股收益（稀释后）MATWPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $1.39 | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.4M | $144.3M |
| 总债务越低越好 | $529.8M | — |
| 股东权益账面价值 | $543.2M | $653.9M |
| 总资产 | $1.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.98× | — |
8季度趋势，按日历期对齐
现金及短期投资MATWPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $31.4M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
总债务MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | $529.8M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MATWPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $543.2M | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | — | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | — | $749.6M | ||
| Q2 24 | — | $879.3M |
总资产MATWPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B |
负债/权益比MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | 0.98× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.0M | — |
| 自由现金流经营现金流 - 资本支出 | $-57.2M | — |
| 自由现金流率自由现金流/营收 | -20.1% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | -1.19× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | $-52.0M | $43.7M | ||
| Q3 25 | — | $60.8M | ||
| Q2 25 | — | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | — | $53.9M | ||
| Q2 24 | — | $53.2M |
自由现金流MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | $-57.2M | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
自由现金流率MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | -20.1% | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
资本支出强度MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
现金转化率MATWPCRX
| Q1 26 | — | — | ||
| Q4 25 | -1.19× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MATW
暂无分部数据
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
